Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
Covered in this story
Call it yourself
No calls on $AVT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avnet →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.